Barclays Upgrades GlaxoSmithKline (GSK) to Overweight
Barclays upgraded GlaxoSmithKline (NYSE: GSK) from Equalweight to Overweight.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $44.41 yesterday.
